- FDA is the source of guidance for U.S. healthcare providers.
- FDA is the source of guidance for U.S. healthcare providers.
- FDA is the source of guidance for U.S. healthcare providers.
- Eli Lilly and Company operates consistent with guidance provided by the FDA.
Eli Lilly advances drug submissions amid major regulatory approvals and revenue growth
- Reports
- 11
- Developments
- 7
- Repetition
- 64%
New informationRepeats or wire copies
What happened
Eli Lilly and Company is advancing the submission process for a new drug candidate to the FDA. Separately, the European Medicines Agency published an opinion on Foundayo, a GLP-1 receptor agonist for weight management and type 2 diabetes, on October 16, 2026. This opinion requires authorization from the European Commission before the medicine can be marketed in Europe. Earlier, Kisunla received full FDA approval in the United States and marketing authorization in Europe.
From finchannel.com
Why it matters
The regulatory progress for Lilly's drug pipeline supports significant financial performance. In the second quarter of 2026, Lilly reported revenue of $23.0 billion, a 48% increase, primarily driven by Mounjaro and Zepbound volume. The EMA opinion on Foundayo is a key step toward expanding market access in Europe.
Eli Lilly and Company operates consistent with guidance provided by the FDA, which serves as the source of guidance for U.S. healthcare providers.
From finchannel.com, aol.com
Who's involved
- Eli Lilly and CompanyAmerican pharmaceutical company advancing drug submissions and reporting high revenue growth.
- FDAThe regulatory agency that formally reviews Eli Lilly's drug development and market activities.
- European Medicines AgencyThe highest regulatory authority in the European Union that issued an opinion on Foundayo.
- EuropeThe continent where European Commission authorization is required for Foundayo.
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- Eli Lilly and CompanySpeculative
Eli Lilly and Company could see future revenue increase as regulatory action paves the way for EU market access.
- EuropeSpeculative
The European market might see increased demand for weight management and type 2 diabetes treatments following European Commission authorization.
Possible ripples
Who this could reach next, traced step by step from the reporting. Possibilities worth considering, not forecasts.- Lilly's pipeline expansion intensifies competition for Novo NordiskLilly's pipeline expansion intensifies competition for Novo NordiskLikely
- Lilly's drug approvals may expand market access across EuropeLilly's drug approvals may expand market access across EuropeLikely
- Lilly's drug submissions require EMA opinion for EU market accessLilly's drug submissions require EMA opinion for EU market accessLikely
- Lilly's expanding GLP-1 pipeline could increase pressure on Viking TherapeuticsLilly's growing GLP-1 franchise may intensify competition for Viking Therapeutics.Possible
How it developed
Newest first. Tap a step to see who reported it.FDA approves Foundayo for Lilly; EMA opinion requires EC authorization.1 source
Regulatory fight over drug classification between FDA and Eli Lilly.1 source
- The FDA has not approved a drug for market, and expert practice related to the drug is based in New York.Sub-event
- Eli Lilly is seeking FDA approval for Zepbound and Mounjaro, tied to a $4 billion production site expansion in Kenosha, Wisconsin.Sub-event
Kisunla gained full FDA approval in the US and marketing authorization in Europe.1 source
- Foghorn's FHD-909 trial advances with Eli Lilly and Company.Sub-event
Lilly is moving forward with the FDA submission process for a new drug.1 source
Keep exploring
The entities involved
- FDA
-
Eli Lilly and Company
American pharmaceutical company
Related events
- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
- Hanmi Pharmaceutical won approval for its homegrown GLP-1 obesity drug, while Eli Lilly expands its market presence.
- Major pharmaceutical companies, including Viking Therapeutics, Eli Lilly, and Novo Nordisk, are advancing their weight loss drug pipelines.
- Both the FDA and the European Medicines Agency govern drug approval processes.
- Eli Lilly and Company received full FDA approval, expanded a safety study into India, and broke ground on a new facility in Houston while competing in the GLP-1 market.